Bhavna PTE Limited Pharmaceutical Import Profile — Singapore (DGFT 2022–2026)

Name: Bhavna PTE Limited Pharmaceutical Import Records from India — 2 Products, $494.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bhavna PTE Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $494.7K Trade | TransData Nexus

Bhavna PTE Limited

Pharmaceutical Importer · Singapore · Brand Names & OTC Products Focus · $494.7K Total Trade · DGFT Verified

Bhavna PTE Limited is a pharmaceutical importer based in Singapore with a total trade value of $494.7K across 2 products in 1 therapeutic categories. Based on 24 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Bhavna PTE Limited sources from 4 verified Indian suppliers, with Accra Pac (india) Private Limited accounting for 57.2% of imports.

Bhavna PTE Limited — Import Portfolio & Supplier Network

Bhavna PTE Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Bhavna PTE Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Accra Pac (india) Private Limited	$110.7K	6	57.2%
Accra Pac India Private Limited	$46.3K	2	23.9%
Crystal Overseas	$28.1K	2	14.5%

What Formulations Does Bhavna PTE Limited Import?

Formulation	Value	Ships
Moov rapid relief spray 150ML (batch	$50.0K	1
Moov rapid relief spray 150ML batch number - b3131e5e / b3132e5e / b3133e5e (1500 cases )	$47.3K	1
Moov rapid relief spray 150ML batch number-b3097e5e qty 1500 cases Pack size 1500 x 48 =	$46.3K	1
Dettol liquid 550ML	$28.1K	2
Moov rapid relief spray 80g batch number - b3136d5e ( 200 cases )	$6.3K	1
Moov pain relief specialist spray 80g	$3.9K	1
Navratna oil (1pcs=270ML) [of	$3.3K	1
Moov pain relief specialist spray 50g	$3.2K	1
Navratna oil (1pcs=450ML) [of	$1.9K	1
Others - dettol liquid (1pcs=250ML)	$1.5K	1
Others - dettol liquid (1pcs=550ML)	$949	1
Others - dettol liquid (1pcs=1ltr)	$879	1
Moov rapid relief spray 150ML batch no	$86	1
Moov rapid relief spray 150ML batch	$85	1

Bhavna PTE Limited imports 14 distinct pharmaceutical formulations. Showing top 14 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Moov	Brand Names & OTC Products	$400.7K	18	1.5%	9
2	Dettol	Brand Names & OTC Products	$94.0K	6	1.1%	13

Bhavna PTE Limited imports 2 pharmaceutical products across 1 categories into Singapore totaling $494.7K.

Bhavna PTE Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Bhavna PTE Limited, established in 1985, is a privately held company headquartered in Singapore. Over the years, it has evolved into a prominent player in the Fast-Moving Consumer Goods (FMCG) sector, specializing in the wholesale import and export of a diverse range of products. The company offers services such as regulatory compliance, brand management, procurement, sales and distribution, as well as logistics and warehousing. (bhavna.com.sg)

While Bhavna PTE Limited's primary focus is on FMCG, it also engages in the importation of pharmaceutical products. This strategic diversification allows the company to leverage its extensive distribution network and market expertise to cater to the pharmaceutical sector's demands. The company's global presence is underscored by its operations in over 75 countries, facilitated through partner offices in regions including Southeast Asia, South Asia, North Asia, the Middle East, and North America. (bhavna.com.sg)

2Distribution Network

Bhavna PTE Limited's distribution network is strategically designed to ensure efficient market penetration and product availability. In Singapore, the company operates from its headquarters at 5 Pereira Road #04-03, Asia Wide Industrial Building, Singapore 368025. (bhavna.com.sg) Additionally, Bhavna maintains a warehouse at 3 Upper Aljunied Link #02-06, Joo Seng Warehouse, Singapore 367902, enhancing its logistical capabilities within the region.

Internationally, Bhavna's distribution centers are strategically located to expedite product delivery and market reach. These centers are situated in key regions, including Southeast Asia, South Asia, North Asia, the Middle East, and North America, facilitating a robust and responsive supply chain. (bhavna.com.sg)

3Industry Role

In Singapore's pharmaceutical supply chain, Bhavna PTE Limited functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, including India, the company plays a pivotal role in ensuring the availability of essential medicinal products in the local market. This position enables Bhavna to bridge the gap between global pharmaceutical manufacturers and the Singaporean healthcare sector, contributing to the diversity and accessibility of pharmaceutical offerings.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Bhavna PTE Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Bhavna PTE Limited's sourcing strategy exhibits a notable concentration, with a significant portion of its pharmaceutical imports originating from a select group of suppliers. The company's total import value from India stands at $495,000 USD, distributed across 24 shipments. The top five products imported include Moov ($401,000 USD, Rank #9, 1.5% share) and Dettol ($94,000 USD, Rank #13, 1.1% share). The top five products collectively account for 100% of the company's pharmaceutical imports, indicating a high level of portfolio concentration.

This sourcing pattern suggests a strategic focus on specific high-demand products, potentially leveraging established relationships with key suppliers. However, the lack of diversification in the supplier base may pose risks related to supply chain disruptions or changes in supplier dynamics. The stability of these relationships is crucial for maintaining a consistent supply of the imported pharmaceutical products.

2Supply Chain Resilience

The resilience of Bhavna PTE Limited's supply chain is closely tied to its reliance on a limited number of suppliers for its pharmaceutical imports. The company's import data reveals that four unique Indian suppliers account for the entirety of its pharmaceutical imports. This concentrated supplier base may expose Bhavna to potential risks, such as supply chain disruptions, price fluctuations, or changes in supplier policies.

Importing Pharmaceuticals into Singapore — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Singapore

1Regulatory Authority & Framework

In Singapore, the Health Sciences Authority (HSA) serves as the primary regulatory body overseeing the importation, supply, and manufacture of health products, including pharmaceuticals. The HSA operates under the Health Products Act and the Medicines Act, ensuring that all health products meet stringent standards of safety, quality, and efficacy. (moh.gov.sg)

The regulatory framework mandates that all medicinal products, including generics, undergo evaluation and approval by the HSA before they can be supplied in Singapore. This process involves assessing the products for compliance with Good Manufacturing Practice (GMP) standards and other regulatory requirements. (moh.gov.sg)

2Import Licensing & GMP

Importers of medicinal products into Singapore must obtain the necessary licenses and approvals from the HSA. For instance, an 'Import License on Consignment Basis' is required for importers who are neither the registrants nor authorized by the registrant of the therapeutic product. This license permits the importation of registered therapeutic products on a per consignment basis. (hsa.gov.sg)

Additionally, the HSA requires evidence of GMP compliance from drug substance manufacturers. Effective October 1, 2024, all new or generic drug applications must be supported by GMP compliance evidence for drug substance manufacturers. This requirement aims to ensure that imported pharmaceutical products adhere to high manufacturing standards.

Bhavna PTE Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Bhavna PTE Limited's focus on importing finished pharmaceutical formulations, such as Moov and Dettol, aligns with market demand for over-the-counter (OTC) products that offer immediate relief and are widely recognized by consumers. The company's strategy to import these specific therapeutic products suggests an understanding of consumer preferences and a commitment to providing accessible healthcare solutions.

2Sourcing Profile

Bhavna's sourcing strategy emphasizes the importation of generic pharmaceutical products, leveraging cost-effective manufacturing in India. By focusing on finished formulations, Bhavna ensures that products are ready for immediate distribution, meeting the needs of the Singaporean market efficiently. This approach allows the company to maintain a streamlined supply chain and offer competitive pricing to consumers.

3Market Positioning

Based on its product mix, Bhavna PTE Limited serves the retail pharmacy segment in Singapore. By importing widely recognized OTC products, the company caters to consumers seeking accessible and effective healthcare solutions. This positioning enables Bhavna to tap into the substantial demand for everyday health products in the retail market.

Seller's Guide — How to Become a Supplier to Bhavna PTE Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Bhavna PTE Limited. By offering high-quality finished pharmaceutical formulations that align with Bhavna's product focus, Indian exporters can integrate into Bhavna's existing supply chain. This partnership would provide access to Singapore's retail pharmacy market, leveraging Bhavna's established distribution network and market presence.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Bhavna PTE Limited must ensure that their products are registered with the HSA and comply with GMP standards. Additionally, products should meet HSA's quality and labeling requirements. Establishing a partnership with Bhavna may also require adherence to specific contractual agreements and alignment with Bhavna's strategic objectives.

3How to Approach

Indian exporters interested in supplying Bhavna PTE Limited should initiate contact through the company's official communication channels, such as email at [email protected]. Engaging in discussions about product offerings, compliance with regulatory standards, and potential collaboration opportunities will

Frequently Asked Questions — Bhavna PTE Limited

What products does Bhavna PTE Limited import from India?

Bhavna PTE Limited imports 2 pharmaceutical products across 1 categories. Top imports: Moov ($400.7K), Dettol ($94.0K).

Who supplies pharmaceuticals to Bhavna PTE Limited from India?

Bhavna PTE Limited sources from 4 verified Indian suppliers. The primary supplier is Accra Pac (india) Private Limited (57.2% of imports, $110.7K).

What is Bhavna PTE Limited's total pharmaceutical import value?

Bhavna PTE Limited's total pharmaceutical import value from India is $494.7K, based on 24 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Bhavna PTE Limited focus on?

Bhavna PTE Limited imports across 1 categories. The largest: Brand Names & OTC Products (100.0%).

Get Full Bhavna PTE Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.